Amiloride-sensitive sodium channel subunit gamma (SCNN1G) (SCNN1G)

Amiloride-sensitive sodium channel subunit gamma (SCNN1G) is a critical component of the epithelial sodium channel (ENaC) complex, which mediates the rate-limiting step of sodium reabsorption in various epithelial tissues, including the distal nephron, respiratory tract, and colon [1][2]. By facilitating the movement of sodium ions across the apical membrane, SCNN1G plays a fundamental role in maintaining total body salt and water homeostasis, thereby regulating extracellular fluid volume and systemic blood pressure [2][3]. Gain-of-function mutations in this gene lead to Liddle syndrome, characterized by severe hypertension, while loss-of-function mutations cause pseudohypoaldosteronism type 1, which involves salt wasting [1][3]. In the lungs, ENaC activity regulates the volume of airway surface liquid; consequently, SCNN1G mRNA has emerged as a therapeutic target for cystic fibrosis and bronchiectasis [4][5]. Novel therapies such as antisense oligonucleotides (ASOs) and siRNA are designed to reduce SCNN1G expression to enhance mucociliary clearance by preventing excessive water absorption [5]. Traditional pharmacological intervention involves small-molecule inhibitors like amiloride that directly block the channel's pore to treat hypertension and edema [1].

Other names

Epithelial sodium channel subunit gammaENaC gamma subunitNonvoltage-gated sodium channel 1 subunit gammaSCNN1GGamma-ENaCPHA1CBESC3

Inhibition of the epithelial sodium channel (ENaC) protein or degradation of SCNN1G mRNA to reduce channel expression